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Abstract
Individuals newly infected with hiv have an increased viral load than at other phases
of hiv infection, which is associated with a higher rate of transmission. Combined
with ignorance about infection status, individuals in the acute phase not only con-
tribute to the growing epidemic but are believed by some to be the driving force
behind new infections. Unfortunately, due to the high costs of testing, individuals
are not routinely tested for acute hiv infection. The matrix pooling algorithm we
present is more economical than individual testing whilst improving accuracy — re-
ducing the number of false positive and false negative test results. Although matrix
pooling may require more tests compared to other pooling algorithms, the significant
increase in accuracy and rapidity with which results are obtained makes this method
more desirable when identifying acute hiv infections, even in resource poor settings.
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1 Introduction
At the end of 2007, unaids estimated that 33.2 million people were infected with
the Human Immunodeficiency Virus (hiv). Of these, two and a half million were
estimated to have occurred in 2007, highlighting the continuing presence of hiv as
a major public health crisis [1]. Because the first few weeks of infection are marked
with high viral loads, which is linked to increased infectiousness, and because newly
infected individuals often are unaware of their infection status, these individuals in
the early stage of infection play a critical role in hiv transmissions [2]. While it is
valuable to identify these individuals for treatment and care, it is more importantly
an opportunity to provide behavior change education to prevent further infections
[[3],[4],[5],[6]]. Additionally, we can use information on recent infections to estimate
hiv incidence, which informs program managers on current trends and the effective-
ness of prevention efforts [7].
Several studies have investigated the impact of expanding hiv testing to include
testing for new (acute) infections using Nucleic Acid Amplification Tests (naat). In
a routine hiv testing environment in North Carolina, the addition of acute testing
identified 23 newly infected individuals (out of more than 100,000 people tested). As
a result, clinicians were able to provide emergency intervention for 48 sex partners and
one fetus [8]. Other studies have found that additional naat testing on individuals in
high risk populations who test negative with hiv antibody tests increases the number
of identified infections by 4 to 10 % [[8],[9],[10],[11], [12]].
Despite the clear clinical benefit of identifying individuals in the early phase of infec-
tion, one hindrance to universal testing is the high costs associated with these tests.
One solution for reducing costs is to use pooling methods. Dorfman first suggested
pooling in 1943 with the primary goal of reducing the overall costs of testing for
2
http://biostats.bepress.com/harvardbiostat/paper58
syphilis [13]. While the Dorfman method reduces the expected number of tests, the
sensitivity of the testing process is also reduced, resulting in an unappealing increase
in false negative test results. In response, Litvak, Tu and Pagano [14] present an
algorithm, T+2 , that improves the accuracy of the pooled testing process by retesting
all of the pools that initially test negative, increasing the overall sensitivity. Such
confirmatory testing does on average require more tests than the standard Dorfman
procedure; however, there remains a significant reduction in the number of tests as
compared to individual testing at low prevalences. Since the introduction of T+2 , the
concept of retesting negative results to improve accuracy has been applied to other
testing algorithms [15].
We propose a matrix pooling algorithm to test for new hiv infections that, at low
prevalence settings, requires fewer tests per sample and yet increases overall accu-
racy when compared to individual testing. Additionally, this proposed method offers
some benefits over other pooling algorithms with retesting. First, the matrix pooling
algorithm reduces the amount of time needed to conduct the testing, in part because
the two tests are performed concurrently, instead of sequentially. Additionally, each
sample is tested in two unique pools, which is advantageous if there is a blocker or
synergistic effect in the samples. The retesting aspect of the matrix pooling algorithm
can lead to more tests compared to other pooling methods, but the increase in costs
results in more individuals’ disease status correctly identified.
For the purposes of this paper, we focus on individuals who test negative on hiv
antibody tests, and assume these individuals are either infected or uninfected with
hiv. Because of the very high sensitivity and specificity of the antibody tests, nearly
all antibody test negative individuals are truly disease free or are in the acute phase of
infection. Further, the prevalence of acute hiv infections in this group is low, the ideal
3
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setting for pooling. A person newly infected with hiv will test antigen positive with
probability Se, the sensitivity of the test, and an uninfected person will test negative
with probability Sp, the specificity of the test. We assume that the sensitivity and
specificity of the test are preserved under the pooling process. Finally, we assume
that all of the tests are independent.
In Section 2 of the paper, we outline current testing methods relevant to acute hiv,
followed by a description of the matrix pooling algorithm in Section 3. In section
4, we discuss the timeliness of all algorithms to deliver positive results. Finally, in
Section 5, we compare our proposed method to other testing methods, showing that
in many settings our method has an improved accuracy and timeliness of results,
though in some cases at the cost of increasing the expected number of tests.
2 Methods of Testing Relevant for Acute HIV
In the past, individual testing has been the standard method for identifying acute
hiv. The drawback is that individual testing for new infections is very expensive.
However, acute hiv infection is the ideal candidate for pooled testing because of the
low prevalence of hiv infections in antibody test negative individuals (due to the
short period in the acute phase of infection when antibodies are not detectable) and
the high cost of the tests. In this section, we describe the sensitivity, specificity and
expected number of tests for two additional testing methods — the modified Dorfman
testing algorithm and T+2— because of their current use in testing for new infections
of hiv or because of their role in the evolution of matrix pooling.
Quinn et al examine a method to test for acute HIV infection similar to Dorfman’s
pooling procedure with the addition of intermediate pools [16]. They combine n
4
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samples into one large pool, and like the Dorfman method, if the pool tests negative,
all of the samples are declared uninfected. If the pool tests positive, then the samples
are divided into m subpools of size k, with k = n/m. The subpools are then tested,
and all samples in subpools that test negative are declared uninfected. The samples in
subpools that test positive are then tested individually. This method has been used in
the identification of individuals in the acute stage of hiv [[9],[17],[8],[10],[18],[11],[12]],
and henceforth, we refer to this method as the modified Dorfman pooling algorithm.
Finally, we present the T+2 algorithm here. Not only is this algorithm used for general
hiv testing, but we utilize this procedure as a substep of matrix pooling. With T+2 ,
the first step begins with testing a pool of n samples. If the pool tests negative, then
the entire pool is retested. If the pool tests negative a second time, then the entire
pool is declared uninfected. If the pool tests positive either at the first test or negative
at the first test and positive at the retest, then the pool is divided into two subpools.
These subpools are equal size if the original pool size, n, is even, and sizes (n− 1)/2
and (n+ 1)/2 if n is odd. Henceforth, this division is referred to as the halving step.
The subpools are then each treated like the original pool, and this testing procedure
continues until each sample is determined to be positive or negative for infection [14].
Let ψi, φi, and E(N)i, for (i = I,MD, or T+2 ) denote the sensitivity, specificity and
expected number of tests for the different testing algorithms. The sensitivity and
specificity of individual testing is equal to the test properties (ψI = Se and φI = Sp)
and the expected number of tests is one (E(N)I = 1). The sensitivity of the mod-
ified Dorfman method is only a function of the test sensitivity (ψMD = S
3
e ). For
a fixed prevalence, the specificity and the expected number of tests (φMD(n,m|p) and
EMD(n,m|p)) are functions of the total number of samples tested and the number of
intermediate pools. These quantities are derived in Appendix A. Finally, the sensitiv-
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ity, specificity and expected number of tests of T+2 (ψT+2 (n), φT
+
2 (n|p), and E(N)T+2 (n|p))
are derived by Litvak et al and for a fixed prevalence are a function of the original
pool size, n ([14],[19]). These values for T+2 are summarized in Appendix A.
3 Matrix Pooling
Phatarfod and Sudbury (1994) and Xie et al (2001) describe a pooling algorithm
that arranges nm samples in an n × m rectangular array and starts by testing the
pools formed by each row and column [[20],[21]]. Both papers discuss the properties
of this algorithm under the assumption of perfect sensitivity and specificity. We
propose a pooling algorithm called matrix pooling (MT+2 ), a square array testing
method that accommodates imperfect tests and is an extension of these algorithms
and T+2 . With MT
+
2 , n
2 samples are randomly placed in an n × n matrix in order
to form two sets of pools: the n pooled rows, r1, . . . , rn, and the n pooled columns,
c1, . . . , cn. For simplicity, we restrict ourselves to a square testing array, but with
obvious modifications, the method can easily be extended to rectangular arrays that
are not square.
We give a brief description of the MT+2 testing algorithm and its properties below, with
detailed derivations of sensitivity, specificity and expected number of tests provided
separately [22]. At the first step of the matrix pooling, we test all the row pools
and all the column pools. We declare the samples at the intersection of negative
row and negative column tests disease free. Samples at the intersection of positive
row and positive column tests are tested individually, with confirmatory retesting
of negative results. Samples at the intersection of discordant row and column pool
tests are submitted to T+2 with the other samples which have discordant results in
6
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Figure 1: Matrix pooling testing algorithm with perfect tests.
The filled circles indicate an infected sample. The positive and negative symbols
indicate row and column pools that test positive and negative, respectively.
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Figure 2: Matrix pooling testing algorithm with imperfect tests.
The filled circles indicate an infected sample. The positive and negative symbols
indicate row and column pools that test positive and negative, respectively.
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the same row, when the row pool has tested positive, and with the other samples
which have discordant results in the same column, when the column pool has tested
positive (Figures 1 and 2). There are three exceptions to the algorithm steps above.
First, if all 2n row and column pools test positive, then each row pool is submitted
to T+2 with a halving step. Second, if r row pools test positive and no column pools
test positive, then each of the r row pools are submitted to T+2 with a halving step.
Finally, if c column pools test positive and no row pools test positive, then each of
the c row pools are submitted to T+2 with a halving step.
Suppose that one of the n2 samples is from an infected individual, and that without
loss of generality, this sample resides in the (n, n) cell. The sensitivity of MT+2 ,
ψMT+2 (n|p), is the probability that this sample will be identified as positive at the end
of MT+2 , with pool size n and disease prevalence p, so that
ψMT+2 (n|p) = 2Se(1− Se)
{
n−1∑
r=0
pos(1)n (r, 0|p)
(
a
n
ψT+2 (a) +
b
n
ψT+2 (b)
)
+ (1)
n−1∑
r=0
n−1∑
c=1
pos(1)n (r, c|p)ψT+2 (n−c)
}
+
S2e
[
pos(1)n (n− 1, n− 1|p)
(
a
n
ψT+2 (a) +
b
n
ψT+2 (b)
)
+{
n−1∑
r=0
n−1∑
c=0
pos(1)n (r, c|p)− pos(1)n (n− 1, n− 1|p)
}
(2Se − S2e )
]
.
Here pos
(1)
n (r, c|p) is the probability that r of the first n − 1 row pools and c of the
first n− 1 column pools test positive and p is the prevalence of disease.
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The specificity of matrix pooling, φMT+2 (n|p), is the probability that an uninfected
sample is identified as disease free at the end of the testing algorithm, and is dependent
on both the matrix size and prevalence of disease. Without loss of generality, we fix
the (n, n) cell to be a sample from an uninfected individual. Then, the specificity of
matrix pooling, φMT+2 (n|p), is
φMT+2 (n|p) = 1−
(
2P (r+n )P (c
−
n )
[
n−1∑
c=1
n−1∑
r=0
pos(1)n (r, c|p)
(
1− φT+2 (n−c|p∗B)
)
+
n−1∑
r=0
pos(1)n (r, 0|p)
{
a
n
(
1− φT+2 (a|p∗B)
)
+
b
n
(
1− φT+2 (b|p∗B)
)}]
+
P (r+n )P (c
+
n )
[
pos(1)n (n− 1, n− 1|p)
{
a
n
(
1− φT+2 (a|p∗A)
)
+
b
n
(
1− φT+2 (b|p∗A)
)}
+
(1− S2p)
{
n−1∑
r=0
n−1∑
c=0
pos(1)n (r, c|p)− pos(1)n (n− 1, n− 1|p)
}])
, (2)
where, given that the (n, n) sample is uninfected, we have the following quantities:
r+n and c
+
n , the probability that the n
th row or nth column test positive; r−n and c
−
n ,
the probability that the nth row or nth column test negative; p∗A, the prevalence of
infected samples in the nth row with a positive column pool test, given that the nth
row tests positive; and p∗B, the prevalence of infected samples in the n
th row with a
negative column pool test, given that the nth row tests positive.
Finally, let E(N)MT+2 (n|p) denote the expected number of tests for matrix pooling with
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an n× n testing matrix and disease prevalence, p. Then,
E(N)MT+2 (n|p) = 2n [posn(0, 0|p)+ (3)
n∑
r=1
r
{
E(N)T+2 (a|pB) + E(N)T+2 (b|pB)
}
posn(r, 0|p) +
n∑
c=1
c
{
E(N)T+2 (a|pB) + E(N)T+2 (b|pB)
}
posn(0, c|p) +
n
{
E(N)T+2 (a|pA) + E(N)T+2 (b|pA)
}
posn(n, n|p) +
n∑
r=1
n∑
c=1
(1− δrc,n2)
{
rcE(N)T+2 (1|pA) + rE(N)T+2 (n−c|pB)+
cE(N)T+2 (n−r|pB)
}
posn(r, c|p)
]
,
with δrc,n2 = 0 if rc = n
2, and where pA is the prevalence of infected samples at
the intersection of positive row pool and column pool tests; pB is the prevalence of
infected samples at the intersection of discordant row and column pool tests; and
posn(r, c|p) denoting the probability that r out of n row pools and c out of n column
pools test positive.
4 Number of Stages Required to Test for Acute
HIV infection
The greatest value of testing for acute hiv infection is the potential of averting new
infections. Therefore, it is necessary to quickly identify an individual in the acute
stage of hiv infection in order to maximize the impact of intervention. Here, we
consider minimizing the number of stages required to identify an infected individual
as acutely infected, where the time required for each stage is the time needed to test
and process the results. Note that this is a separate measure from the sensitivity, or
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the probability correctly identifying an infected individual. Here, we only consider
those correctly identified as infected, and determining how many stages of testing
were required for this identification.
Let Si denote the number of stages required to classify an infected individual as
infected. Individual testing requires the fewest stages, as it only uses one test at one
stage to classify an infected individual as such, SI = 1. With the modified Dorfman
algorithm, an infected sample must test positive at three stages — first in the master
pool, which is divided into subpools if it tests positive; second in the subpool; and
then individually if the subpool tests positive. Thus, the modified Dorfman method
requires three stages to correctly identify an infected individual, SMD = 3.
For T+2 , the number of stages required to correctly identify an infected sample is a
function of the original pool size and test sensitivity. For each n, n = 2k−1, then any
infected sample must be subdivided into k−1 additional subpools beyond the master
pool to be determined positive, requiring a minimum of k and maximum 2k stages
to be determined positive at the end of T+2 . For 2
k−1 ≤ n < 2k, an infected sample
requires k − 1 subpools (k levels total) with probability (2k − n)/n and k subpools
(k + 1 levels total) with probability 1 − (2k − n)/n. Therefore, for any pool size n,
the minimum number of stages to determine an infected sample as positive is k and
the maximum number is 2(k + 1).
The expected number of stages to identify an infected sample as positive for T+2 is
ST+2 (n) =
1
ψT+2 (n)
2 (k+1)∑
s=k
s P (S = s
⋂
T+|D+)
=
1
ψT+2 (n)
S+
T+2 (n)
,
12
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where S+
T+2 (n)
is the expected number of stages from the joint distribution for the
number of stages and the probability that the sample is identified as infected at the
end of T+2 . Therefore, we standardize this expected value by the probability that an
infected sample tests positive, or the sensitivity of T+2 , to obtain the final quantity,
ST+2 (n). For the joint expected value, we have
S+
T+2 (n)
=
2k − n
n
2k∑
i=k
i
(
k
i− k
)
Ske (1− Se)i−k
+
(
1− 2
k − n
n
) 2(k+1)∑
j=k+1
j
(
k + 1
j − (k + 1)
)
S(k+1)e (1− Se)j−(k+1).
The number of stages to correctly identify an infected individual with matrix pool-
ing is a function of both the initial matrix size, the prevalence of disease, and test
sensitivity and specificity. As with T+2 , we first look at the expected number of
stages with joint distribution of the number of stages and testing positive, condi-
tional on the sample being infected, S+
MT+2 (n|p)
. We then standardize this quan-
tity by the sensitivity of matrix pooling for the pool size and prevalence, so that
SMT+2 (n|p) = S
+
MT+2 (n|p)
/ψMT+2 (n|p).
At the first round of testing, each sample is tested twice, in a row and column pool.
However, this testing occurs simultaneously, so that the round of testing is considered
one stage, and the probability that the sample is not identified as negative at this
stage is 2Se − S2e . If the infected sample is at the intersection of a positive row and
column pool (with probability S2e ), and not all rows and columns test positive, then
the sample is tested individually, with a confirmation for negative test. This results
in an added expected number of additional stages of 3Se−2S2e . If the sample is at the
intersection of discordant row and column tests (with probability (1 − Se)2) or if all
13
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of the rows and columns test positive, then the sample is submitted to T+2 following
the steps outlined in section 3. Therefore, the expected number of stages to correctly
identify an infected sample is
S+
MT+2 (n|p)
= (2Se − S2e ) + 2Se(1− Se)
{
n−1∑
r=0
pos(1)n (r, 0|p)
(
a
n
ST+2 (a) +
b
n
ST+2 (b)
)
+
n−1∑
r=0
n−1∑
c=1
pos(1)n (r, c|p)ST+2 (n−c)
}
+
S2e
[
pos(1)n (n− 1, n− 1|p)
(
a
n
ST+2 (a) +
b
n
ST+2 (b)
)
+{
n−1∑
r=0
n−1∑
c=0
pos(1)n (r, c|p)− pos(1)n (n− 1, n− 1|p)
}
(3Se − 2S2e )
]
,
where a = dn/2e and b = bn/2c.
5 Comparison of Matrix Pooling to Individual
Testing, Modified Dorfman, and T+2
In this section, we first compare the accuracy, as measured by the false positive
and false negative predictive values, and the expected number of tests per result of
MT+2 to individual testing, the modified Dorfman pooling algorithm and T
+
2 . The
false negative predictive value (fnpv) is the probability that a sample identified as
negative at the end of a testing algorithm is truly infected, and for testing method i,
is written as
FNPVi =
(1− ψi)p
(1− ψi)p+ φi(1− p) .
14
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Minimizing the fnpv in the case of acute hiv infection is imperative in order maximize
the opportunities for risky behavior intervention during this highly infectious stage.
In the case of screening blood, identifying an acutely infected individual prevents an
infected unit of blood from entering the blood supply.
The false positive predictive value (fppv) is the probability that a sample is deter-
mined to be positive is truly uninfected, and is expressed as
FPPVi =
(1− φi)(1− p)
(1− φi)(1− p) + ψip.
Generally, minimizing this value is of second priority to minimizing the fnpv, arguing
that eventually the individual falsely identified as positive will be determined to be
uninfected. However, in the case of hiv, where infection can be highly stigmatized, a
false positive result can lead to extreme emotional and, in some cases, physical harm.
Therefore, it is important to consider minimizing this quantity as well.
Finally, a reduction in the expected number of tests per result should translate into
decreased costs in the testing procedure. A reduction in cost can increase the feasi-
bility of screening for acute infections, even in resource constrained environments.
Tables 1–3 show the analytic results for the fppv, fnpv, and expected number of
tests per result for three prevalence levels: 0.03%, 0.3% and 3.0%. These prevalences
of acute infection in hiv antibody negative individuals approximate those observed
in the general testing population in North Carolina, in the STD clinic population in
San Francisco, and in the STD/dermatology clinic population in Malawi, respectively
([8], [10], [12]). We restrict our discussion to these levels of acute infection because
they represent an extreme range of incidence rates — from a rate of new infections in
a general testing population in a low prevalence setting to the rate of new infections
15
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in a high risk population in a high prevalence setting. Our tables include two test
accuracies, Se = Sp = 0.95 and Se = Sp = 0.99, reflecting the high accuracy in the
testing methods for acute hiv.
We consider two scenarios of the modified Dorfman pooling algorithm (one with a
master pool size of 90 and nine subpools, one with 50 samples in the master pool
and five subpools), reflecting the pooling procedure used in the North Carolina and
Malawi studies referenced to above. We present results for four matrix sizes — 4× 4,
8×8, 12×12, and 16×16. Any matrix size larger than 16×16 requires more than 200
samples, which in many setting would take too long to collect. Finally, we present
T+2 for pool sizes n = 4, 8, 12, and 16 for easy comparison to matrix pooling, and for
n = 50 and 90 for comparison to the modified Dorfman method. This paper presents
the analytic results in Tables 1 - 3, but each has been confirmed with simulations.
For the prevalence levels and combinations of sensitivity and specificity shown, ma-
trix pooling out performs individual testing in all three areas: false positive predictive
values, false negative predictive values and expected number of tests per result. Com-
pared to individual testing, matrix pooling reduces the false positive predictive value
by 20–80%, when test sensitivity and specificity is equal to 0.95, and 67–99% when
the test sensitivity and specificity is equal to 0.99. The false negative predictive value
is 8 – 10 times higher when testing samples individually, if the sensitivity and speci-
ficity is 0.95, and as much as fifty times higher if the sensitivity and specificity is
0.99. Even with this sizable increase of accuracy, matrix pooling requires between 30
– 85% fewer tests per result compared to individual testing.
Matrix pooling does not greatly impact the false positive predictive values compared
to the modified Dorfman method at the lowest prevalence level when the sensitivity
and specificity are 0.95. At the remaining prevalence levels and sensitivity/specificity
16
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Table 1: Comparing matrix pooling to other testing algorithms, p = 3/10,000
prevalence Expected Number
= FPPV FNPV of Tests
3/10,000 (×10−6) per Result
Individual Testing 0.9943 (0.9711) 15.79 (3.03) 1 (1)
MD(90,9) 0.5366 (0.0903) 42.81 (8.91) 0.0247 (0.0179)
MD(50,5) 0.5132 (0.0860) 42.81 (8.91) 0.0320 (0.0255)
T+2 (90) 0.1287 (0.0257) 5.64 (0.23) 0.0331 (0.0287)
T+2 (50) 0.1286 (0.0255) 5.01 (0.20) 0.0537 (0.0464)
T+2 (16) 0.1311 (0.0203) 3.73 (0.15) 0.1549 (0.1329)
T+2 (12) 0.2134 (0.0267) 3.49 (0.14) 0.2049 (0.1757)
T+2 (8) 0.2978 (0.0208) 2.99 (0.12) 0.3049 (0.2615)
T+2 (4) 0.7634 (0.0448) 2.25 (0.09) 0.6026 (0.5196)
MT+2 (16) 0.4957 (0.0140) 1.75 (0.06) 0.1539 (0.1316)
MT+2 (12) 0.5015 (0.0122) 1.71 (0.06) 0.2045 (0.1750)
MT+2 (8) 0.5295 (0.0105) 1.66 (0.06) 0.3067 (0.2617)
MT+2 (4) 0.7860 (0.0348) 1.58 (0.06) 0.6123 (0.5220)
The false positive and false negative predictive values and expected number of tests
per result, for a sensitivity and specificity of 95% and sensitivity and specificity of
99% (in parentheses).
17
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Table 2: Comparing matrix pooling to other testing algorithms, p = 3/1,000
prevalence Expected Number
= FPPV FNPV of Tests
3/1,000 (×10−5) per Result
Individual Testing 0.9459 (0.7705) 15.83 (3.04) 1 (1)
MD(90,9) 0.4053 (0.0856) 42.97 (8.94) 0.0750 (0.0653)
MD(50,5) 0.3698 (0.0806) 42.96 (8.94) 0.0702 (0.0627)
T+2 (90) 0.1281 (0.0256) 5.66 (0.23) 0.0861 (0.0781)
T+2 (50) 0.1274 (0.0254) 5.02 (0.20) 0.0999 (0.0896)
T+2 (16) 0.1100 (0.0202) 3.74 (0.15) 0.1865 (0.1627)
T+2 (12) 0.1390 (0.0264) 3.50 (0.14) 0.2331 (0.2028)
T+2 (8) 0.1303 (0.0203) 3.00 (0.12) 0.3275 (0.2832)
T+2 (4) 0.2977 (0.0227) 2.25 (0.09) 0.6161 (0.5331)
MT+2 (16) 0.2167 (0.0188) 1.76 (0.06) 0.1778 (0.1498)
MT+2 (12) 0.1852 (0.0122) 1.73 (0.06) 0.2248 (0.1912)
MT+2 (8) 0.1624 (0.0067) 1.67 (0.06) 0.3239 (0.2765)
MT+2 (4) 0.3026 (0.0074) 1.58 (0.06) 0.6270 (0.5359)
The false positive and false negative predictive values and expected number of tests
per result, for a sensitivity and specificity of 95% and sensitivity and specificity of
99% (in parentheses).
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Table 3: Comparing matrix pooling to other testing algorithms, p = 3/100
prevalence Expected Number
= FPPV FNPV of Tests
3/100 (×10−4) per Result
Individual Testing 0.6299 (0.2462) 16.25 (3.12) 1 1
MD(90,9) 0.3185 (0.0740) 44.47 (9.20) 0.3675 (0.3655)
MD(50,5) 0.3080 (0.0720) 44.43 (9.20) 0.3500 (0.3511)
T+2 (90) 0.1232 (0.0248) 5.83 (0.23) 0.4777 (0.4772)
T+2 (50) 0.1225 (0.0246) 5.18 (0.21) 0.4702 (0.4388)
T+2 (16) 0.1042 (0.0197) 3.86 (0.16) 0.4709 (0.4524)
T+2 (12) 0.1260 (0.0255) 3.61 (0.14) 0.4926 (0.4524)
T+2 (8) 0.1056 (0.0197) 3.09 (0.12) 0.5392 (0.4874)
T+2 (4) 0.1229 (0.0199) 2.32 (0.09) 0.7456 (0.6632)
MT+2 (16) 0.3210 (0.0812) 1.81 (0.06) 0.5731 (0.5240)
MT+2 (12) 0.2381 (0.0515) 1.78 (0.06) 0.5274 (0.4696)
MT+2 (8) 0.1504 (0.0252) 1.74 (0.06) 0.5425 (0.4754)
MT+2 (4) 0.1087 (0.0084) 1.64 (0.06) 0.7801 (0.6827)
The false positive and false negative predictive values and expected number of tests
per result, for a sensitivity and specificity of 95% and sensitivity and specificity of
99% (in parentheses).
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combinations, with few exceptions, matrix pooling improves the false positive pre-
dictive values as much as 66% over modified Dorfman (99% when sensitivity and
specificity are 0.99). More importantly, the false negative predictive value of the
modified Dorfman method is approximately 25 fold larger when the sensitivity and
specificity are 0.95 compared to matrix pooling (nearly 150 times larger when sensi-
tivity and specificity are 0.99). However, this great increase in accuracy comes at a
cost. Matrix pooling does require two to ten times more tests per result compared to
the modified Dorfman method.
The comparison of matrix pooling to T+2 is much more complicated. The fppv is
consistently the same or lower with T+2 compared to MT
+
2 , as much as a sixth the
rate. The fnpv of T+2 is marginally larger than MT
+
2 , by an order of 1.3 – 3.6
times larger. However, the fnpv of T+2 is still considerably lower than individual
testing and the modified Dorfman algorithm. When the T+2 pool size is the same as
matrix pooling row or column pool sizes then both algorithms require approximately
the same number of tests per result. However, larger T+2 pool sizes results in savings
similar to what we observe with large pool sizes and the modified Dorfman algorithm,
especially for lower prevalences.
The true benefit of MT+2 over T
+
2 is in the timeliness of correctly identifying an infected
individual, allowing more time for interventions to avert new infections. Figure 3
shows the average number of stages required for identifying an infected individual
as positive for T+2 and MT
+
2 (ST+2 (n) and SMT+2 (n|p)). On average, matrix pooling
requires between 2–3 stages to correctly identify an infected individual, for all matrix
sizes and test sensitivity between 0.90–1.00. Note that we only present the graph for
p = 3/10, 000 and Sp = 0.99, but the results remain the same for the other prevalence
levels and specificities presented in this paper. Even at the smallest pool size, n = 4,
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Figure 3: The number of stages required to correctly identify an infected sample.
The red lines display results for T+2 ; the black lines for MT
+
2 (n=4, dotted; n=8,
dashed; n=12, solid; n=16, dot-dashed). Sp = 0.99, p = 3/10, 000.
T+2 requires at least three stages. This number increases so that at the largest pool
size, n = 90, T+2 requires, on average, approximately eight stages, potentially losing
the value of testing for acute infection for the purpose of intervention.
These results beg the question, how do we select a testing strategy for acute hiv in
practice? For now, we will focus on selecting a testing algorithm based only on two
parameters - the expected number of tests per result and the number of people in the
acute phase of infection correctly identified by the testing algorithm. We no longer
discuss T+2 , because of the increased amount of time required to obtain the positive
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results for an infected individual at the pool sizes where there is a clear benefit of T+2
over matrix pooling in terms of reducing the expected number of tests per sample.
For each prevalence level, we present the one modified Dorfman algorithm and one
matrix pooling strategy that minimizes the expected number of tests per result, since
the false negative predictive values within a testing method are approximately con-
stant for a fixed prevalence, sensitivity and specificity. Suppose we anticipate testing
100,000 individuals. Tables 4 and 5 show the number of infected people correctly
and incorrectly identified by each algorithm. These tables also present the number of
tests required per infected sample identified and the additional number of tests per
additional infected sample identified with matrix pooling compared to the modified
Dorfman.
As noted before, the modified Dorfman is a cheaper method per case identified. How-
ever, by employing the more accurate matrix pooling algorithm, we can identify more
acute cases, potentially averting more infections. For the sensitivity and specificity
of 0.95, this requires on average 3,151 tests per additional case identified in the low-
est prevalence setting, and 43.2 tests per additional case identified in the highest
prevalence setting. Assuming a naat costs between $30 – $80, this results in approx-
imately $95,000 – $252,000 per additional case identified in low prevalence settings
and $1,300 – $3,500 in high prevalence settings. At a higher test sensitivity and speci-
ficity (0.99), it is more expensive to identify an additional case — as much as $383,250
- $1,022,000 in low prevalence areas and $4,020 – $10,720 in high prevalence areas. It
is difficult to place a numeric value on identifying a new hiv infection. Factors such
as the estimated number of infections averted per case identified, both in primary
and secondary infections, influence this value. One must also consider the monies
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saved in terms of treatment and care for the infections averted. Finally, identifying
and intervening with acute hiv infections has huge potential impact for curbing the
epidemic, emphasizing the value of prioritizing accuracy over cost. Ultimately, all of
these factors must be considered on a case-by-case basis when determining the most
appropriate algorithm for a particular scenario.
6 Conclusion
There are multiple tests available to identify an individual as hiv infected, either
through antibody or antigen detection. The choice of test, or combination of tests,
depends on the goals of testing as well as the availability of resources. Antibody
detecting tests are most commonly used to identify individuals who are hiv infected
for the purpose of clinical intervention because of the low cost. In many contexts,
especially low prevalence situations, very few additional cases would be identified
with antigen detection through naat. However, recent infection is marked with high
viral load and can indicate recent risky behavior. This biologically supports evidence
that individuals with acute hiv infection are drivers of the epidemic [2]. Therefore,
identifying these individuals provides an excellent opportunity for interventions to
prevent further infections.
Changing the way that a test is administered by pooling samples reduces the expected
number of tests, and therefore makes detection of acute hiv affordable. If the single
goal is to save money, then the modified Dorfman testing algorithm is the superior
method compared to individual testing and matrix pooling. However, because of
the extreme risks associated with missing an individual who is truly in the early
phases of hiv infection, and negative consequences of falsely informing a person that
25
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he/she is hiv positive, it is also important to factor in the accuracy of the test. In
almost all cases presented here, the matrix pooling method performs better than the
modified Dorfman algorithm and individual testing with respect to the false positive
predictive value and matrix pooling has far better false negative predictive values at
the plausible prevalences, sensitivities, and specificities.
The fppv and fnpv of T+2 are very similar to that of matrix pooling, sometimes
offering a slight advantage over MT+2 and at times performing slightly worse. This
is not surprising since matrix pooling is an extension of the T+2 testing algorithm.
However, MT+2 offers the clear benefit of identifying an infected individual as positive
more quickly, which again may lead to faster, more effective interventions. Also,
matrix pooling has the advantage of testing each sample in at least two unique pools.
This property is beneficial if the chemical compositions of different samples can react,
risking one sample blocking or amplifying the effect of another.
The matrix pooling testing algorithm is more complicated to implement when com-
pared to individual testing and the modified Dorfman method. However, automating
the procedure will allow testing for acute hiv infections using MT+2 with minimal
human error introduced. Another possible limitation is that we derive our theory
under the strong assumption that the sensitivity and specificity of an individual test
is not compromised by the formation of pools. This is a common assumption when
testing for acute hiv, and a testable assumption if one wants to use matrix pooling
for other diagnostic settings. Also, if the sensitivity is slightly reduced by pooling,
it is possible to adjust our overall algorithm estimates of sensitivity accordingly and
appropriately compare to the other proposed methods.
Because of the decrease in costs, pooling techniques are currently being used to test
for acute hiv infections. However, the accuracy of the testing is compromised by
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the process. The matrix pooling method introduced here provides a more affordable
alternative to testing as compared to individual testing, whilst reducing the false
positive and false negative predictive values. Given these desirable testing properties,
adopting the matrix pooling method is recommended, especially since it can make
testing for acute hiv infection possible in many settings where it would otherwise not
be feasible.
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Appendix A: Properties of the Pooling Methods
A.1 Modified Dorfman
In this section, we present the derivations of the sensitivity, specificity and expected
number of tests for the modified Dorfman method. In order for an infected sample
to be declared positive via the modified Dorfman pooling method [13], it must test
positive three times, first in the master pool, then in the subpool, then individually.
Therefore, the sensitivity of the modified Dorfman method is ψMD = S
3
e .
To determine the specificity of the modified Dorfman algorithm, fix one sample in the
pool to be uninfected. Let D+1 be the event that the master pool tests positive and
D−1 be the event that the master pool tests negative, given one sample is negative.
Then
P (D−1 ) = Sp(1− p)n−1 + (1− Se)
{
1− (1− p)n−1} (A.1)
P (D+1 ) = 1− P (D−1 ).
Let D+2 be the event that the subpool tests positive and D
−
2 be the event that the
subpool tests negative, given one sample is uninfected and the master pool tests
positive. Then, similarly
P (D−2 ) = Sp(1− p∗)k−1 + (1− Se)
{
1− (1− p∗)k−1} (A.2)
P (D+2 ) = 1− P (D−2 ),
where now p∗ is the prevalence in the subpool, excluding the one sampled fixed to be
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uninfected, given that the master pool tests positive. Thus,
p∗ = P (sample i is positive|D+1 and one sample is negative)
=
Sep
Sep+ [(1− p)n−2(1− Sp) + Se{1− (1− p)n−2}] (1− p) . (A.3)
The specificity in the modified Dorfman method is the probability that the sample
fixed to be uninfected is identified as disease negative by either the master pool
testing negative, the subpool testing negative in the event that master pool tests
positive, or the individual sample testing negative in the event that the master pool
and subsequently the subpool tests positive. Using the above notation, the specificity
of the modified Dorfman method is,
φMD(n,m|p) = P (D−1 ) + P (D
+
1 )
{
P (D−2 ) + P (D
+
2 )Sp
}
. (A.4)
To determine the expected number of tests for this method, let G+1 be the event that
the master pool tests positive. Then
P (G+1 ) = (1− Sp)(1− p)n + Se {1− (1− p)n} . (A.5)
Let G+2 be the event that the subpool tests positive. Then,
P (G+2 ) = Sp(1− p′)k + (1− Se)
{
1− (1− p′)k} , (A.6)
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where p′ is the prevalence of infected samples in the subpool, given the master pool
tests positive and thus
p′ =
Sep
Sep+ [(1− p)n−1(1− Sp) + Se{1− (1− p)n−1}] (1− p) . (A.7)
The required number of tests using the modified Dorfman testing algorithm is one,
if the master pool tests negative, 1 +m + jk if the master pool tests positive and j
of the m subpools test positive. Therefore, using the previous notation, the expected
number of tests for the modified Dorfman method is
E(N)MD(n,m|p) = 1 + P (G+1 )
{
m+ P (G+2 )(mk)
}
(A.8)
A.2 T+2
Here we summarize the sensitivity, specificity and expected number tests as derived
elsewhere.
The sensitivity of T+2 is
ψT+2 (n) = (2Se − S
2
e )
[
a
n
ψT+2 (a) +
b
n
ψT+2 (b)
]
with a = dn/2e and b = bn/2c. To start the iteration, we have ψT+2 (1) = (2Se − S2e ).
For specificity, we first define the probability of identifying an uninfected sample as
positive, conditional on the number of infected samples in the remaining n−1 samples
in the pool, y. Here,
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FP (n|Y = 0) =
[
a
n
FP (a|Y = 0) + b
n
FP (b|Y = 0)
]
(1− S2p)
FP (n|Y = c) =
[
a
n
νa∑
i=λa
(
a−1
i
)(
b
c−i
)(
n−1
c
) FP (a|Y = i) + b
n
νb∑
j=λb
(
b−1
j
)(
a
c−j
)(
n−1
c
) FP (a|Y = j)] (2Se − S2e ),
where a and b are defined above and λa = max(0, c − (m − a)), νa = min(a − 1, c),
λb = max(0, c− (m− b)), and νb = min(b− 1, c). The iteration starts with FP (1|y =
0) = 1− S2p . Now, we have the false positive rate, conditional on p, as
FP (n|p) =
n−1∑
i=0
FP (n|Y = i)P (Y = i), and
φT+2 (n|p) = 1− FN(n|p) (A.9)
where P (Y = c) is based on the binomial distribution of n−1 samples and a prevalence
p.
Finally, we first express the expected number of tests for T+2 conditioned on the
number of positive samples in the pool, so that
E(N)T+2 (n|Y=0) = 1 + Sp + (1− S
2
p)
[
E(N)T+2 (a|Y=0) + E(N)T+2 (b|Y=0)
]
E(N)T+2 (n|Y=c) = 2− Se + (2Se − S
2
e )
[
ν∑
i=λ
(
a
i
)(
b
c−i
)(
n
c
) [E(N)T+2 (a|Y=i)
+E(N)T+2 (b|Y=c−i)]
]
(2Se − S2e ),
where a = dn/2e, b = bn/2c, λ = max(0, c − b), and ν = min(a, c). The iteration
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starts with E(N)T+2 (1|Y=0) = 1+Sp and E(N)T+2 (1|Y=1) = 2−Se. It follows immediately
that the expected number of tests, conditional on the prevalence of disease, p, is
E(N)T+2 (n|p) =
n∑
i=0
E(N)T+2 (n|Y=i)P (Y = i).
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